...
首页> 外文期刊>Medicine. >Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus
【24h】

Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus

机译:肝切除或经动脉化学栓塞治疗肝细胞癌合并门静脉肿瘤血栓

获取原文
获取原文并翻译 | 示例
           

摘要

The role of hepatic resection in hepatocellular carcinoma (HCC) with accompanying portal vein tumor thrombus (PVTT) remains controversial. This study aimed to evaluate the surgical outcomes of hepatic resection compared with those of transarterial chemoembolization (TACE) in HCC patients. A retrospective study was conducted using the medical records of 230 HCC patients with portal vein invasion who underwent hepatic resection (96 patients) or TACE (134 patients). The baseline characteristics, tumor characteristics, clinicopathological parameters, and overall survival rates were compared between the 2 groups. The baseline and tumor characteristics were comparable between the hepatic resection and TACE groups. The overall complication rate was 35.4% in the hepatic resection group, which was significantly lower than that in the TACE group (73.0%, P<0.001). However, the serious complication rate (grade 3) in the hepatic resection group was 13.5%, which was significantly higher than that in the TACE group (P = 0.003). The cumulative overall survival rates at 1, 3, and 5 years in the hepatic resection group were 86.5%, 60.4%, and 33.3%, respectively. These rates were much higher than those in the TACE group (1-year: 77.6%; 3-year: 47.8%; and 5-year: 20.9%; P = 0.021). The long-term survival was notably better in the patients with types I and II PVTT than in the patients with types III and IV PVTT (P<0.05). The univariate and multivariate analyses indicated that types III and IV PVTT and TACE may have contributed to the poor overall survival following surgery. In HCC patients with PVTT and compensated liver function, hepatic resection is a safe and effective surgical protocol, particularly for patients with type I or II PVTT.
机译:肝切除在伴有门静脉肿瘤血栓(PVTT)的肝细胞癌(HCC)中的作用仍存在争议。本研究旨在评估HCC患者肝切除术与经动脉化疗栓塞(TACE)的手术结局。回顾性研究使用230例行肝切除术(96例)或TACE(134例)的门静脉侵犯的HCC患者的病历进行。比较两组的基线特征,肿瘤特征,临床病理参数和总生存率。肝切除术和TACE组之间的基线和肿瘤特征相当。肝切除组总并发症发生率为35.4%,明显低于TACE组(73.0%,P <0.001)。但是,肝切除组的严重并发症发生率(3级)为13.5%,显着高于TACE组(P = 0.003)。肝切除组在1年,3年和5年的累计总生存率分别为86.5%,60.4%和33.3%。这些比率大大高于TACE组(1年:77.6%; 3年:47.8%; 5年:20.9%; P = 0.021)。 I型和II型PVTT患者的长期生存率明显优于III型和IV型PVTT患者(P <0.05)。单因素和多因素分析表明,III型和IV型PVTT和TACE可能导致了术后总体生存率低下。对于具有PVTT和肝功能补偿的HCC患者,肝切除术是一种安全有效的手术方案,尤其是对于I型或II型PVTT的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号